Literature DB >> 21178452

Interferon interplay helps tissue cells to cope with SARS-coronavirus infection.

Thomas Kuri1, Friedemann Weber.   

Abstract

SARS coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome, is a versatile pathogen armed with a host of factors countering the antiviral type I interferon (IFN) system. Hence, tissue cells infected with SARS-CoV are unable to launch an IFN response. Plasmacytoid dendritic cells, however, produce high levels of IFN after infection. We recently demonstrated that minute amounts of IFN applied before infection (IFN priming) can ameliorate the IFN response of tissue cells to SARS-CoV. IFN priming of SARS-CoV-infected cells activated genes for IFN transcription, IFN signaling, antiviral effector proteins, ubiquitinylation and ISGylation, antigen presentation, and other cytokines and chemokines, whereas IFN treatment or infection alone had no major effect. Thus, the IFN which is produced by plasmacytoid dendritic cells could enable tissue cells to at least partially overturn the SARS-CoV-induced block in innate immune activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21178452     DOI: 10.4161/viru.1.4.11465

Source DB:  PubMed          Journal:  Virulence        ISSN: 2150-5594            Impact factor:   5.882


  3 in total

Review 1.  Systems biology unravels interferon responses to respiratory virus infections.

Authors:  Andrea L Kroeker; Kevin M Coombs
Journal:  World J Biol Chem       Date:  2014-02-26

Review 2.  From SARS to COVID-19: What we have learned about children infected with COVID-19.

Authors:  Meng-Yao Zhou; Xiao-Li Xie; Yong-Gang Peng; Meng-Jun Wu; Xiao-Zhi Deng; Ying Wu; Li-Jing Xiong; Li-Hong Shang
Journal:  Int J Infect Dis       Date:  2020-05-07       Impact factor: 3.623

Review 3.  Potential of algal metabolites for the development of broad-spectrum antiviral therapeutics: Possible implications in COVID-19 therapy.

Authors:  Rimjhim Sangtani; Atreyee Ghosh; Hem C Jha; Hamendra Singh Parmar; Kiran Bala
Journal:  Phytother Res       Date:  2020-11-18       Impact factor: 6.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.